分组1 - Foghorn Therapeutics Inc. reported a quarterly loss of $0.34 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.28, representing an earnings surprise of -19.72% [1] - The company posted revenues of $9.25 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 14.87%, and showing significant growth from $2.86 million in the same quarter last year [2] - Over the last four quarters, Foghorn Therapeutics has surpassed consensus EPS estimates two times and topped consensus revenue estimates twice [2] 分组2 - The stock has increased by approximately 1.7% since the beginning of the year, while the S&P 500 has declined by 0.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.26 on revenues of $9.06 million, and for the current fiscal year, it is -$0.96 on revenues of $42.83 million [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is currently in the bottom 42% of over 250 Zacks industries, indicating potential underperformance compared to higher-ranked industries [8]

Financial Performance - The company has reported net losses of $74.3 million and $86.6 million for the years ended December 31, 2025 and 2024, respectively, with an accumulated deficit of $632.5 million as of December 31, 2025[379]. - The company expects to incur significant operating losses in the foreseeable future as it continues to support research and development activities[415]. - The company reported a net loss of $74.3 million for the year ended December 31, 2025, which contributed to cash used in operating activities[422]. Revenue and Collaboration - The company has not generated any revenue from product sales to date and does not expect to do so in the near future[383]. - The company received an upfront payment of $300.0 million from Eli Lilly as part of the collaboration agreement, along with an equity investment of $80.0 million[370]. - The collaboration with Lilly includes a 50/50 profit and expense share for U.S. programs and tiered royalties on ex-U.S. sales starting in the low double-digit range[386]. - Collaboration revenue increased to $30.9 million for the year ended December 31, 2025, up from $22.6 million in 2024, reflecting continued advancement of programs under the Lilly Collaboration Agreement[409]. Expenses and Cost Management - The company expects significant increases in operating expenses as it continues to develop its product candidates and expand its research capabilities[380]. - Total operating expenses decreased to $117.3 million in 2025 from $125.3 million in 2024, primarily due to a reduction in research and development expenses[408]. - Research and development expenses were $85.5 million for the year ended December 31, 2025, down from $94.5 million in 2024, attributed to the discontinuation of certain clinical trials and decreased facility costs[410]. - General and administrative expenses decreased to $27.6 million in 2025 from $28.4 million in 2024, mainly due to reduced facility and IT-related expenses[411]. Cash Flow and Financing - The company reported net cash used in operating activities of $86.1 million for the year ended December 31, 2025, compared to $100.4 million for 2024[421]. - The company had cash, cash equivalents, and marketable securities totaling $158.9 million as of December 31, 2025[417]. - Net cash provided by investing activities was $112.0 million for the year ended December 31, 2025, primarily due to $243.3 million of marketable securities maturing[424]. - The company raised approximately $50.0 million from the January 2026 offering before expenses, selling 2,030,314 shares of Common Stock and Pre-Funded Warrants[420]. - The company provided net cash from financing activities of $1.0 million for the year ended December 31, 2025, primarily from the sale of common stock under its ATM Facility[426]. - The company may need to seek additional financing sooner than expected if capital resources are depleted, which could negatively impact its financial condition[429]. Deferred Revenue and Impairments - The company has recognized total deferred revenue of $337.8 million related to the Lilly Collaboration Agreement, with $249.2 million remaining on the balance sheet as of December 31, 2025[390]. - The company experienced a decrease in deferred revenue of $30.9 million for the year ended December 31, 2025, impacting cash flows from operating activities[422]. - A non-cash impairment of long-lived assets charge of $5.9 million was recorded in 2025, related to the abandonment of leasehold improvements[413]. Future Outlook and Development - The company is currently working on more than seven programs, with one clinical-stage drug candidate in Phase 1 development, targeting over 500,000 cancer patients[367]. - The company anticipates that its research and development expenses may increase unpredictably due to geopolitical and economic factors[395]. - The company expects expenses to increase significantly due to ongoing clinical activities, including the Phase 1 clinical trial of FHD-909 partnered with Lilly[428]. - The company anticipates that its current cash and marketable securities will be sufficient to fund operations for at least twelve months[428].

Core Insights - Foghorn Therapeutics is advancing its clinical-stage programs, particularly focusing on FHD-909 for SMARCA4-mutant cancers, with a strong emphasis on non-small cell lung cancer (NSCLC) [1][3] - The company has successfully completed a $50 million registered direct financing, enhancing its financial position and extending its cash runway into the first half of 2028 [2][4] Financial Overview - As of December 31, 2025, Foghorn had cash, cash equivalents, and marketable securities totaling $158.9 million, which supports operations until mid-2028 [2][19] - Collaboration revenues increased to $30.9 million for the year ended December 31, 2025, up from $22.6 million in 2024, driven by advancements in programs under the Lilly Collaboration Agreement [19] - Research and development expenses decreased to $85.5 million in 2025 from $94.5 million in 2024, primarily due to reduced costs in FHD-286 and other operational efficiencies [19] Clinical Development - FHD-909 is a first-in-class oral SMARCA2 selective inhibitor, currently in a Phase 1 trial targeting NSCLC patients with SMARCA4 mutations, where treatment outcomes are typically poor [6][15] - The trial is progressing well, with the first patient dosed in October 2024, and preclinical data suggests enhanced anti-tumor activity when combined with pembrolizumab and KRAS inhibitors [6][7] - The Selective CBP and EP300 degrader programs are on track for IND-enabling studies in 2026, targeting various cancers including ER+ breast cancer and multiple myeloma [1][8][9] Strategic Collaborations - Foghorn is collaborating with Lilly under a 50/50 co-development and co-commercialization agreement for its selective SMARCA2 oncology program, which includes both a selective inhibitor and a selective degrader [7] - The collaboration also encompasses three discovery programs from Foghorn's Gene Traffic Control platform, indicating a robust partnership aimed at developing novel oncology treatments [7] Leadership Changes - In February 2026, Foghorn appointed Ryan Maynard as Chief Financial Officer, bringing over 25 years of experience in financial strategy and capital markets execution within the biopharmaceutical sector [5]

Summary of Foghorn Therapeutics FY Conference Call Company Overview - **Company**: Foghorn Therapeutics (NasdaqGM:FHTX) - **Industry**: Biotechnology, specifically focused on oncology and chromatin regulatory systems - **Key Personnel**: Dr. Adrian Gottschalk, President and CEO Core Points and Arguments - **Clinical Stage Focus**: Foghorn is a clinical-stage biotech company primarily focused on oncology, utilizing the chromatin regulatory system, which has been found to play a significant role in various diseases, including cancer, autoimmunity, and neurodegeneration [3][4] - **Drug Development**: The company has developed capabilities in protein degradation, with most advanced proprietary programs being protein degraders. The chromatin regulatory system is crucial for gene expression regulation [5][6] - **Partnership with Eli Lilly**: Foghorn has a 50/50 partnership with Eli Lilly on the FHD-909 program, which is currently in the dose escalation phase. The collaboration is significant, being one of the largest preclinical oncology deals [7][8] - **Pipeline Progress**: Foghorn is on track for IND-enabling studies for its selective CBP and EP300 programs later this year, with an expected IND for an I&I program in 2027 [7][8][36] Clinical Trials and Data - **SMARCA2 Program**: The SMARCA2 program is currently dosing escalated, with sites open in the US, Japan, France, Germany, Spain, and South Korea. The maximum tolerated dose has not yet been reached [9][10] - **Patient Demographics**: The study focuses on non-small cell lung cancer patients with SMARCA4 mutations, particularly those in the fourth or fifth line of treatment, indicating a high unmet medical need [12][13][14] - **Efficacy Data**: Preliminary data suggests that patients with SMARCA4 mutations have significantly lower response rates and overall survival compared to wild-type patients, highlighting the need for effective treatments in this population [13][14][15] Proprietary Pipeline - **CBP and EP300 Programs**: Foghorn is developing selective protein degraders for CBP and EP300, which are histone acetyltransferases. The lead molecule for CBP, FHT-171, has shown promising pre-development results [18][19][20] - **Long-acting Formulations**: The company is working on long-acting injectable formulations for its VHL-based degraders, aiming for subcutaneous delivery once a week [23][29] - **ARID1B Degrader**: Foghorn is also developing an ARID1B degrader, which has shown potential across various solid tumor malignancies. The goal is to achieve in vivo proof of concept by 2026 [31][32][34] Financial Position - **Funding**: Foghorn recently completed a registered direct offering of $50 million, which is expected to cover operational expenses for approximately two quarters. This offering was priced at a 30% premium to the trading price at the time, indicating investor confidence [37][38] Additional Insights - **Market Positioning**: The company is strategically positioned to address significant unmet needs in oncology, particularly for patients with specific genetic mutations [12][14] - **Future Directions**: Foghorn is exploring induced proximity mechanisms and has plans to provide updates on these developments in the coming years [36] This summary encapsulates the key points discussed during the Foghorn Therapeutics FY Conference Call, highlighting the company's focus on innovative oncology treatments and its strategic partnerships.

Core Insights - Foghorn Therapeutics Inc. has appointed Ryan Maynard as Chief Financial Officer effective February 23, 2026, bringing over 25 years of executive experience in the biopharmaceutical sector [1][2][3] Company Overview - Foghorn Therapeutics is focused on developing a new class of medicines that target genetically determined dependencies within the chromatin regulatory system, utilizing its proprietary Gene Traffic Control® platform [4] Leadership and Experience - Ryan Maynard has a strong background in financial strategy and operational performance, having previously served as CFO at Cara Therapeutics, where he led financial strategy and strategic transactions [2][3] - He has raised over $1 billion through public and private financings and played a significant role in the FDA approval and commercial launch planning of TAVALISSE [3] - Maynard has also executed a reverse merger and raised $37.5 million through a non-dilutive royalty deal at Cara Therapeutics [3] Strategic Goals - The company aims to advance its first-in-class pipeline and is currently in dose escalation for its lead program in partnership with Lilly, while also preparing its selective degrader portfolio for clinical trials [2][3]

Core Viewpoint - Foghorn Therapeutics Inc. is participating in the Guggenheim Emerging Outlook: Biotech Summit, highlighting its innovative Gene Traffic Control platform aimed at treating serious diseases, particularly in oncology [1]. Group 1: Company Overview - Foghorn Therapeutics is a clinical-stage biotechnology company focused on developing a new class of medicines that correct abnormal gene expression [1]. - The company utilizes its proprietary Gene Traffic Control platform to identify and validate drug targets within the chromatin regulatory system [3]. - Foghorn is developing multiple product candidates specifically in the oncology sector [3]. Group 2: Event Participation - Management will present at the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026, at 3:00 p.m. EST [2]. - A webcast of the presentation will be available for 30 days on the company's website [2]. - The management team will also engage in one-on-one meetings during the summit [4].

Regulatory Developments - Atossa Therapeutics, Inc. (ATOS) received Orphan Drug Designation from the U.S. FDA for (Z)-endoxifen to treat Duchenne muscular dystrophy, leading to a 12.98% increase in stock price to $0.69 [1] - ImmunityBio, Inc. (IBRX) reported that enrollment in its QUILT-2.005 trial for bladder cancer exceeded expectations, with over 85% enrollment, anticipating full enrollment by Q2 2026 and FDA submission by year-end 2026, resulting in a 9.43% stock price increase to $6.04 [2] Financing Updates - Foghorn Therapeutics Inc. (FHTX) closed a $50 million registered direct financing at a 30% premium, contributing to a 4.02% increase in stock price to $6.26 [4] - Femasys Inc. (FEMY) received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement, allowing until July 13, 2026, for compliance, leading to a 10.68% increase in stock price to $0.72 [3] Investor Sentiment - Theravance Biopharma, Inc. (TBPH) saw a 5.00% increase in stock price to $21.01 despite no new announcements [5] - Daré Bioscience, Inc. (DARE) experienced a modest gain of 1.04% to $1.95 without any new news [4]

Financing Details - Foghorn Therapeutics Inc. closed a $50 million registered direct financing at a 30% premium, selling 2,030,314 shares at $6.71 per share [1] - The offering included pre-funded warrants for up to 5,421,250 shares at $6.7099 each and series warrants for up to 3,725,782 shares at $13.42 and another 3,725,782 shares at $20.13 [1] - The gross proceeds from the offering were approximately $50 million, excluding proceeds from the exercise of series warrants [1] Investor Participation - Existing shareholders such as BVF Partners, Deerfield Management, Flagship Pioneering, and a leading biotech mutual fund participated in the financing [2] - No underwriter or placement agent was involved in the offering [2] Company Overview - Foghorn Therapeutics is focused on developing a new class of medicines that target genetically determined dependencies within the chromatin regulatory system [4] - The company utilizes its Gene Traffic Control platform to identify and validate potential drug targets, with multiple product candidates in oncology [4]

Collaboration and Financials - FHD-909 is being developed in collaboration with Lilly, with a significant agreement signed in December 2021, including $300 million cash and $80 million in common stock[9] - The collaboration includes a 50/50 U.S. economic split on the SMARCA2-target program and potential royalties ranging from low double-digit to 20s[9] - The collaboration with Lilly is expected to yield up to $1.3 billion in potential milestones across three programs[9] - Foghorn's cash position is $158.9 million, providing a runway into 2028, with a potential market impact on approximately 2.5 million patients[48] Clinical Development and Pipeline - FHD-909 is currently in Phase 1 clinical trials, targeting SMARCA4-mutant cancers, which account for approximately 10% of NSCLC and up to 5% of all solid tumors[12][14] - FHD-909 aims to become a first-line treatment for SMARCA4-mutant NSCLC, addressing significant unmet medical needs in this patient population[15][16] - The company is advancing multiple preclinical assets towards INDs, including selective inhibitors for SMARCA2, CBP, EP300, and ARID1B[10] - The selective SMARCA2 inhibitor FHD-909 is partnered with Lilly, with a $380 million upfront payment and is currently in Phase 1 trials[48] Efficacy and Mechanism of Action - The overall response rate (ORR) for patients with SMARCA4 mutations is significantly lower compared to those without, highlighting the urgent need for targeted therapies[17] - FHD-909 leverages a synthetic lethal relationship between SMARCA2 and mutated SMARCA4, representing a promising strategy in precision medicine[12][13] - FHD-909 demonstrated significant tumor regression in SMARCA4-mutant NSCLC models at tolerated doses, with a maximum dose of 60 mg/kg[52] - In vivo studies show that combining FHD-909 with cisplatin and pemetrexed enhances antitumor effects, resulting in significant tumor regression[54] - FHD-909 exhibits synergistic activity when combined with KRAS inhibitors in vitro, indicating potential for enhanced therapeutic efficacy[56] - FHD-909 sensitized tumor cells to pembrolizumab, resulting in enhanced anti-tumor activity, with pembrolizumab alone showing no effect compared to vehicle control[59] - Combination of FHD-909 with olomorasib demonstrated synergistic antitumor activity with a significant p-value of <0.05 in NCI-H2030 models[57] - FHD-909 combined with pan-KRAS inhibitor resulted in sustained tumor regression, also showing a significant p-value of <0.05 for the combination group[58] Preclinical Assets and Future Developments - The selective CBP degrader, FHT-171, is IND-ready in 2026, with a focus on CBP-dependent and EP300-mutant cancers, showing increased tolerability compared to non-selective compounds[24] - IND-enabling studies for selective EP300 degraders are planned for 2026, focusing on improved tolerability and deeper efficacy responses compared to non-selective molecules[32] - The selective EP300 degrader EP300d-007 shows superior efficacy in IMiD resistant multiple myeloma models, achieving deeper responses compared to pomalidomide and inobrodib[38] - The ARID1A mutation incidence in endometrial cancers is approximately 66,000 per year in the U.S., with ARID1B being a major synthetic lethal target[41] - The ARID1B degrader treatment has shown effects on downstream target genes, progressing towards in vivo proof-of-concept[47] - The company is advancing multiple preclinical assets towards INDs, including selective degraders for ARID1B and EP300[48] Safety and Tolerability - No significant impact on platelet counts was observed following treatment with selective CBP and EP300 degraders, indicating a favorable safety profile[35] - The long-acting injectable formulation of CBPd-171 enables weekly subcutaneous delivery, showing comparable efficacy to daily injections in gastric cancer models[30] Degradation Mechanisms - Selective degradation of CBP leads to reduced expression of estrogen receptor target genes, resulting in cancer cell growth inhibition[25] - The selective EP300 degrader shows anti-proliferative activity across a broad range of hematological malignancies, with approximately 70% of tested cell lines being sensitive[33] - EP300 degradation results in significant tumor growth inhibition in multiple myeloma and DLBCL models, with fold selectivity exceeding 1000x for certain compounds[34] - Experimental kinetic analysis indicates that degradation rates are crucial for determining the efficiency of protein degraders, with slower rates leading to partial degradation[62] - Prelude's SMARCA2 (VHL) degrader achieved improved degradation metrics compared to SMARCA2 (CRBN) degrader, indicating faster action at high concentrations[64] - Foghorn's analysis of degradation rates aligns with published data, confirming the efficacy of their degraders in achieving significant protein degradation[65]

Core Insights - Foghorn Therapeutics has successfully raised $50 million in equity financing, which is set to close on January 13, 2026, at a 30% premium to the stock price on January 9, 2026, indicating strong investor confidence in the company's vision and execution [2][3] - The company is advancing its Phase 1 dose-escalation trial of FHD-909, targeting SMARCA4-mutant cancers, particularly non-small cell lung cancer (NSCLC), which has a poor prognosis [1][4] - Foghorn is on track to make its Selective CBP and EP300 degrader programs IND-ready in 2026, with promising preclinical data supporting their efficacy in various cancers [1][10][11] Financial Overview - The company has a strong balance sheet with approximately $208.9 million in cash, cash equivalents, and marketable securities, which will support ongoing investments in its pipeline and extend its cash runway into the first half of 2028 [1][12] - The recent equity financing will allow the company to continue its strategic objectives and development of its oncology pipeline [2][3] Pipeline Development - FHD-909 is a first-in-class oral SMARCA2 selective inhibitor, showing high selectivity and potential for inducing tumor death while sparing healthy cells, particularly in SMARCA4-mutant cancers [4] - The Selective CBP degrader program is focused on ER+ breast cancer and aims to overcome challenges associated with dual inhibition of CBP/EP300, while the Selective EP300 degrader program targets hematological malignancies [6][7] - The Selective ARID1B degrader program is also advancing, targeting ARID1A-mutated cancers, with potential for oral delivery and selective degradation [8][16] Strategic Collaborations - Foghorn is collaborating with Lilly on a 50/50 co-development and co-commercialization agreement for its selective SMARCA2 oncology program, which includes both a selective inhibitor and a selective degrader [5]